Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Anlon Healthcare IPO Review, Analysis, Good or Bad

By Jagat Joshi
August 25, 2025

The opening date of the Anlon Healthcare IPO is August 26, 2025, while the closing date is August 29, 2025. The Anlon Healthcare IPO price band is set between ₹86 to ₹91 per share. At the same time, the face value of the IPO is ₹10 each. The company filed a DRHP to raise funds of around ₹121.03 crores through an Initial public offering (IPO).

As an investor, deciding whether to invest in an IPO can often be challenging. If you are confused and worried about whether to Apply for the Anlon Healthcare IPO, do not worry. Here are 10 important key points and an in-depth, detailed Anlon Healthcare IPO review that will help you make the decision.

Strengths and Weaknesses of Anlon Healthcare IPO

Strengths:

Over the years, the company has shown a strong product portfolio and a scalable business.

The company consists of a strong, experienced team who have played a significant role in shaping and developing the business.

Anlon Healthcare is committed to maintaining the quality standards by incorporating in-house testing, quality control, and quality assurance.
At their manufacturing facility, they have quality check systems to ensure consistent quality, efficiency, and safety.

Weaknesses:

The company needs to follow the strict technical specifications, quality standards, and undergo regular inspections and audits in order to fulfill the customer’s requirements. If they fail to meet these requirements can badly impact the business, like they may lose the business from them or face order cancellation.
Anlon Healthcare mostly generates its revenue from via limited number of customers; losing any of those customers can negatively impact the business, financial condition, and cash flows.
The company generates its revenue from selling its products to different segments of the pharmaceutical industry. In case if demand for their products falls, or a new drug makes them outdated can badly affect the overall condition and cash flow.
In previous years, the company has experienced negative cash flows.

Anlon Healthcare IPO Details

IPO Size:	₹121.03 crores
Offer-for-sale:	No Offer-for-Sale
Fresh issue:	₹121.03 crores
Price band:	₹86 to ₹91
Subscription:	Opens on August 26, 2025, and the closing date is August 29, 2025
Purpose of IPO:	Fresh Issue

Anlon Healthcare IPO Open and closing dates?

The Anlon Healthcare IPO will open for subscription on August 26, 2025, and close on August 29, 2025.

What is the size of the Anlon Healthcare IPO?

The company planned to raise around ₹121.03 crores in funds via an IPO. This IPO comprises only a fresh issue of ₹121.03 crores with a face value of ₹10 each.

What are the subscription details of the Anlon Healthcare IPO?

The Anlon Healthcare IPO price range is set at ₹86 to ₹91 per share. In this IPO, a total of 164 shares were available in 1 lot size for the minimum Retail category, and for the maximum retail category, 2,132 shares in 13 lot sizes were available. For the S-HNI Minimum category, 2,296 shares were available in 14 lot sizes. While for the B-HNI Minimum category, 11,152 shares were available in 68 lot sizes.

To invest in this IPO, each investor category has specific investment amounts:

Retail Investors: Minimum investment of ₹14,924 and maximum investment of ₹1,94,012.
Small HNI (S-HNI): Minimum investment of ₹2,08,936.
Big HSI (S-HNI): A minimum investment of ₹10,14,832 is required.

What is the Anlon Healthcare IPO listing Date?

Anlon Healthcare is a Mainboard IPO shares will be listed on September 3, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).

What are the objectives of the Anlon Healthcare IPO Issue?

The objective behind raising funds via a fresh issue is to utilize the funding for capital expenditure requirements for the Proposed Expansion. Some of the funds will be used for the Full or partial repayment and/or prepayment of certain outstanding secured borrowing (term loan)availed by the Company. Lastly, the remaining funds will be used for the General corporate purposes.

About Anlon Healthcare

Incorporated in 2013, Anlon Healthcare Limited is one of the leading chemical manufacturing companies involved in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs). APIs are used across multiple healthcare products, including tablets, capsules, ointments, syrups, nutraceuticals, personal care items, and animal health products. The company’s portfolio covers pharmaceutical intermediates, active pharmaceutical ingredients (APIs), nutraceutical APIs, and specialty ingredients for personal care and veterinary applications.

Anlon Healthcare is also one of the few Indian companies manufacturing loxoprofen sodium dihydrate, an API commonly prescribed for severe pain management such as arthritis, back pain, frozen shoulder, dental pain, and post-surgical recovery. As of January 31, 2025, the company employed 105 people (excluding trainees) along with 8 contract workers. At the time of filing its DRHP, it offered 65 commercial products, with another 28 at the pilot stage and 49 undergoing laboratory testing.

Anlon Healthcare IPO Financials

The company reported revenue of ₹66.69 crores in 2024 against ₹113.12 crores in 2023. The company reported a profit of ₹9.66 crores in 2024 against a profit of ₹5.82 crores in 2023.

Anlon Healthcare IPO Promoters

Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia are the promoters of the company.

Who are the Anlon Healthcare IPO lead managers and registrar?

Interactive Financial Services Ltd is the lead manager of Anlon Healthcare, while KFin Technologies Limited is the registrar to the issue.

Should you apply or not for the Anlon Healthcare IPO?

The Anlon Healthcare IPO looks promising as the company manufactures pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”), a raw material used in pharmaceutical formulations, tablets, capsules, ointments, and syrups. Moreover, Anlon Healthcare is one of India’s few manufacturers of loxoprofen sodium dihydrate.

As of now, the company’s portfolio comprises 65 commercialised products and 28 products. The good quality systems and plans to use the IPO money for expansion, working capital, and reducing debt make them a trusted company to invest in. If we talk about the company’s finances, in FY23-24, the revenue fell from ₹112 crore to ₹66 crore, however, the Profit After Tax grew from ₹5.8 crore to ₹9.6 crore, respectively.

Now, if you ask whether you should apply for the Anlon Healthcare IPO, investors seeking exposure to pharmaceutical intermediates and looking for potential listing gains or long-term holding may find this IPO worth considering.

This implies that Anlon Healthcare Limited may offer high returns and can provide excellent long-term gains. However, in the end, we always recommend doing a good financial background check on the company to avoid potential risks and losses. Please invest cautiously and at your own risk.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.